Integral Derivatives’s Alexion Pharmaceuticals ALXN Stock Holding History

Integral Derivatives’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$981K	Sell	8,800 -200	-2%	-$23.9K	0.02%	240
2017 Q4	$1.08M	Sell	9,000 -8,000	-47%	-$974K	0.02%	460
2017 Q3	$2.38M	Sell	17,000 -16,800	-50%	-$2.28M	0.04%	269
2017 Q2	$4.11M	Buy	33,800 +28,000	+483%	+$3.26M	0.08%	143
2017 Q1	$703K	Sell	5,800 -13,700	-70%	-$1.77M	0.01%	631
2016 Q4	$2.39M	Buy	19,500 +17,000	+680%	+$2.08M	0.04%	278
2016 Q3	$306K	Sell	2,500 -8,300	-77%	-$1.07M	0.01%	775
2016 Q2	$1.26M	Buy	+10,800	New	+$1.53M	0.03%	347
2015 Q4	–	Sell	-2,800	Closed	-$438K	–	1275
2015 Q3	$438K	Sell	2,800 -2,200	-44%	-$401K	0.01%	741
2015 Q2	$904K	Buy	+5,000	New	+$863K	0.02%	552
2014 Q1	–	Sell	-12,100	Closed	-$1.61M	–	1658
2013 Q4	$1.61M	Buy	+12,100	New	+$1.45M	0.02%	594

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Integral Derivatives's ALXN Position: Q1 2018 in Review

Integral Derivatives sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 15,780 shares — an estimated $1.89M sold.

Integral Derivatives first reported a position in ALXN in Q4 2013 and held it in 6 quarters. The position peaked at $2.91M in Q3 2017. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

Integral Derivatives reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Integral Derivatives sold 15,780 Alexion Pharmaceuticals shares in Q1 2018, an estimated $1.89M.
Integral Derivatives first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 6 quarters.
Integral Derivatives's Alexion Pharmaceuticals position peaked at $2.91M in Q3 2017.
596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.